Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Innate Pharma S.A. (IPH.PA)
Marseille, FR
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.47% | -2.89% | +34.33% | +10.41% | -7.89% | +0.75% | -18.17% | -42.43% | -47.11% | -87.51% | -66.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-77.9% Q4'25: -109.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+9.8% Q4'25: -172.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,284.2% Q4'25: +1,045.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-2,058.0% Q4'25: +1,540.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +348.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+10.3% Q4'25: +13.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.40× Q4'25: -0.18× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 1 EPS Ana. |
Dec 2027 6 Rev. Ana. 1 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.47M
est: 16.65M (-25.1%)
|
907.0K
est: 7.62M (-88.1%)
|
17.91M
est: 47.00M (-61.9%)
|
56.16M
est: 49.82M (+12.7%)
|
32.63M
est: 53.82M (-39.4%)
|
79.89M
est: 72.19M (+10.7%)
|
68.97M
est: 97.88M (-29.5%)
|
69.77M
est: 77.05M (-9.4%)
|
12.11M
est: 45.66M (-73.5%)
|
49.64M
est: 69.41M (-28.5%)
|
51.90M
est: 33.79M (+53.6%)
|
12.62M
est: 39.52M (-68.1%)
|
2.79M
est: 14.85M (-81.2%)
|
31.22M
4.20M – 100.01M
+110.2% YoY
|
64.75M
6.30M – 267.00M
+107.4% YoY
|
41.13M
41.13M – 41.13M
-36.5% YoY
|
191.52M
20.96M – 732.46M
+365.6% YoY
|
349.04M
38.19M – 1.33B
+82.2% YoY
|
| EBITDA |
-1.91M
est: -9.47M (+79.8%)
|
-17.14M
est: -4.34M (-295.1%)
|
-8.09M
est: -26.74M (+69.7%)
|
10.83M
est: -28.34M (+138.2%)
|
-35.65M
est: -30.62M (-16.4%)
|
-3.30M
est: -41.07M (+92.0%)
|
-20.86M
est: -55.69M (+62.5%)
|
13.31M
est: -43.84M (+130.3%)
|
-43.23M
est: -25.98M (-66.4%)
|
-61.30M
est: -39.49M (-55.2%)
|
-1.84M
est: -27.27M (+93.3%)
|
-50.99M
est: -31.90M (-59.9%)
|
-55.97M
est: -11.99M (-367.0%)
|
-25.19M
-80.71M – -3.39M
-110.2% YoY
|
-52.26M
-215.49M – -5.08M
-107.4% YoY
|
-33.20M
-33.20M – -33.20M
+36.5% YoY
|
-154.58M
-591.16M – -16.91M
-365.6% YoY
|
-281.70M
-1.08B – -30.82M
-82.2% YoY
|
| EBIT |
-2.70M
est: -10.38M (+74.0%)
|
-19.48M
est: -4.75M (-309.8%)
|
-6.57M
est: -29.31M (+77.6%)
|
13.07M
est: -31.07M (+142.1%)
|
-39.98M
est: -33.56M (-19.1%)
|
5.15M
est: -45.02M (+111.4%)
|
1.58M
est: -61.04M (+102.6%)
|
1.08M
est: -48.05M (+102.2%)
|
-47.83M
est: -28.48M (-67.9%)
|
-65.72M
est: -43.29M (-51.8%)
|
-6.93M
est: -27.93M (+75.2%)
|
-52.98M
est: -32.67M (-62.2%)
|
-57.36M
est: -12.28M (-367.2%)
|
-25.81M
-82.68M – -3.47M
-110.2% YoY
|
-53.53M
-220.73M – -5.21M
-107.4% YoY
|
-34.01M
-34.01M – -34.01M
+36.5% YoY
|
-158.33M
-605.53M – -17.32M
-365.6% YoY
|
-288.55M
-1.10B – -31.57M
-82.2% YoY
|
| Net Income |
-2.89M
|
-19.65M
|
-6.71M
est: 6.08M (-210.3%)
|
12.64M
est: 7.98M (+58.3%)
|
-48.39M
est: -22.26M (-117.4%)
|
3.05M
est: -12.16M (+125.1%)
|
-20.76M
est: -3.71M (-459.2%)
|
-63.98M
est: -28.68M (-123.1%)
|
-52.81M
est: -42.98M (-22.9%)
|
-58.10M
est: -62.63M (+7.2%)
|
-7.57M
est: -34.05M (+77.8%)
|
-49.47M
est: -46.05M (-7.4%)
|
-49.18M
est: -49.18M (+0.0%)
|
-29.01M
-105.51M – 3.56M
+41.0% YoY
|
9.69M
-677.1K – 20.05M
+133.4% YoY
|
-51.37M
-171.26M – 5.78M
-630.3% YoY
|
30.40M
-4.80M – 142.02M
+159.2% YoY
|
97.91M
-15.45M – 457.39M
+222.1% YoY
|
| SGA |
10.67M
est: 14.86M (-28.2%)
|
12.82M
est: 6.80M (+88.4%)
|
5.88M
est: 41.94M (-86.0%)
|
9.33M
est: 44.45M (-79.0%)
|
16.18M
est: 48.03M (-66.3%)
|
19.25M
est: 64.42M (-70.1%)
|
49.58M
est: 87.34M (-43.2%)
|
18.99M
est: 68.76M (-72.4%)
|
25.52M
est: 40.75M (-37.4%)
|
22.44M
est: 61.94M (-63.8%)
|
11.75M
est: 54.98M (-78.6%)
|
17.72M
est: 64.31M (-72.4%)
|
11.00M
est: 24.16M (-54.5%)
|
50.80M
6.83M – 162.74M
+110.2% YoY
|
105.36M
10.25M – 434.48M
+107.4% YoY
|
66.94M
66.94M – 66.94M
-36.5% YoY
|
311.66M
34.10M – 1.19B
+365.6% YoY
|
567.97M
62.15M – 2.17B
+82.2% YoY
|
| EPS |
-0.07
|
-0.39
|
-0.13
est: 0.08 (-273.3%)
|
0.23
est: 0.10 (+133.5%)
|
-0.89
est: -0.27 (-224.1%)
|
0.05
est: -0.15 (+134.6%)
|
-0.31
est: -0.05 (-576.8%)
|
-1.05
est: -0.35 (-196.8%)
|
-0.74
est: -0.53 (-39.5%)
|
-0.73
est: -0.30 (-139.8%)
|
-0.09
est: -0.42 (+77.7%)
|
-0.61
est: -0.36 (-70.6%)
|
-0.55
est: -0.55 (+0.0%)
|
-0.25
-1.18 – 0.04
+54.1% YoY
|
0.05
-0.01 – 0.22
+119.0% YoY
|
-0.41
-1.92 – 0.06
-954.2% YoY
|
0.34
-0.05 – 1.59
+182.9% YoY
|
1.10
-0.17 – 5.12
+222.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan E. Dickinson | Chief Executive Officer & Director | 939.6K | male |
| Sonia Quaratino | Executive Vice President & Chief Medical Officer | 188.1K | — |
| Yannis Morel | Executive Vice President & Chief Operating Officer | 163.7K | male |
| Jean Jacques Fournié | Founder | — | male |
| Alessandro Moretta | Founder | — | male |
| Odile Belzunce | VP, Chief of Compliance & Operations Officer and Interim Head of HR | — | female |
| Stephanie Cornen | Vice President of Investor Relations, Communication & Commercial Strategy | — | female |
| Marc Bonneville | Founder | — | — |
| François Romagné | Founder | — | — |
| Frederic Lombard | Senior Vice President & Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IPH.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
